Solid Biosciences Inc. (SLDB)

USD 4.03

(-9.64%)

Market Cap (In USD)

161.01 Million

Revenue (In USD)

-

Net Income (In USD)

-96.01 Million

Avg. Volume

388.15 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
4.0-15.05
PE
-
EPS
-
Beta Value
1.928
ISIN
US83422E2046
CUSIP
83422E105
CIK
1707502
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Alexander G. Cumbo
Employee Count
-
Website
https://www.solidbio.com
Ipo Date
2018-01-26
Details
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.